Radiopaque Strategy for Bone Injectable Substitute


Article Preview

The purpose of this study ass to investigate the addition of round 80-200m granules shape radiopaque agents (RA) to synthetic Injectable Bone Substitute to improve contrast performance for minimal invasive surgery MIS. Composites were obtained by mixing BaSO4, Bi2O3, Lu2O3 or GdPO4 with calcium deficient apatite CDA which decompose during sintering process in BCP (60% HA, 40% β-TCP). Each composite was characterized: by XRD, FTIR. Biocompatibility was tested in vitro and in vivo in bony site (3 weeks implantation in rats). Primary results show that the suitable radiopaque BCP/RA composite (radiopacity intensity, biological responses) appeared to be BCP/Ba. Next works will complete the current studies on biological performance in association with different kind of resorbable injectable bone substitute as suspension, gel or calcium phosphate cements.



Key Engineering Materials (Volumes 361-363)

Main Theme:

Edited by:

Guy Daculsi and Pierre Layrolle




S. Baroth et al., "Radiopaque Strategy for Bone Injectable Substitute", Key Engineering Materials, Vols. 361-363, pp. 39-42, 2008

Online since:

November 2007




[1] O. Gauthier et al. (2005) Biomaterials 26, Issue 27: 5444-43.

[2] M.P. Ginebra, et al. (2002) Biomaterials 23, Issue 8: 1873-82.

[3] Catharina S. J. van Hooy-Corstjens et al. (2004) Biomaterials 25, Issue 13: 2657-67.

[4] S.M. Kurtz et al. (2005) Biomaterials 26, Issue 17: 3699-712.

[5] G. Daculsi, et al. (2005) ITBM-RBM 26, issue 3: 218-22 Figure 5: MOVAT Pentachrome staining (A/B/C/D) and polarized light (E) BCP/Ba BCP/Bi BCP/Lu BCP/Gd BCP/Ba E.